Squamous Cell Carcinoma of Head and Neck research hub
10 indexed studies · 6 currently recruiting
- active not recruitingPHASE1, PHASE2
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
This study is testing a new treatment called TG4050 for a type of head and neck cancer. It's looking at how safe and effective the treatment is in patients who have already had their main cancer treated.
United States · France · Spain - recruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
This study is testing a new medicine, TH9619, for people with advanced cancers like bowel, head and neck, lung, and stomach cancer. It's the first time TH9619 is being given to people, and doctors want to find the safest and most effective dose.
France · Spain · United Kingdom - recruitingPHASE1, PHASE2
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
This study looks at new ways to treat head and neck cancer using a drug called Amivantamab, sometimes combined with other treatments. It aims to find out if these treatments are safe and how well they work for people with different types of head and neck cancer.
United States · China · France - recruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
United States · France · South Korea - recruitingPHASE1, PHASE2
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This study is testing a new drug, UCB4594, for advanced cancers. It's the first time it’s being used in people. Researchers want to find the safest dose, understand side effects, and see if it can shrink certain tumours by helping the body's immune system.
United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies
This study is testing a new medicine, INCA32459, for people with certain advanced cancers like melanoma or lymphoma. It's an early-stage study to see how the medicine works and if it's safe.
Belgium · Spain · Italy - ongoing, recruitingTherapeutic exploratory (Phase II)
EORTC 2120-HNCG: Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck squamous cell carcinoma: a randomized phase II study (Ravina)
This study looks at a new drug, xevinapant, given with radiotherapy for older patients with advanced head and neck cancer. We want to see if this combination helps more people live longer without their cancer coming back. It's a Phase II study, meaning we're testing its effectiveness and safety.
Italy · Slovenia · Germany - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies
This early-stage study is testing a new combination of medicines, REGN6569 and Cemiplimab, to see if they are safe and work for adults with advanced head and neck squamous cell carcinoma. It's looking for people willing to try a new treatment approach.
Spain - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - recruitingPHASE3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
This study is looking at a new treatment for head and neck cancer that has come back or spread. It combines a new drug, amivantamab, with standard treatments to see if it works better than standard care alone to fight the cancer.
United States · Australia · Austria